Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SB27 vs Keytruda in metastatic non-squamous NSCLC (SB27-3004)
jRCT2061230106Phase 3Active, not recruiting
- Sponsor
- Samsung Bioepis
- Start
- May 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, double-blind trial in non-squamous non-small cell lung cancer comparing SB27 arm with Keytruda arm (2 arms). Primary endpoint: Objective Response Rate at Week 24. Started May 2024; status: active, not recruiting.
02
Drugs
QL2107pembrolizumab
03
Conditions
non-squamous non-small cell lung cancer
Beyond the preview
Go deeper on jRCT2061230106.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2061230106.